Patent · US Active

Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof

US9255146B2 · kind B2 · utility

0Cited by

6References

6Claims

0Family size

Assignees

Abb Vie Inc. · US
Abb Vie Deutschland Gmbh & Co. KG · DE

Inventors

Mario Mezler · Ludwigshafen, DE
Achim Moeller · Grünstadt, DE
Reinhold Mueller · Schifferstadt, DE
Bernhard Mueller · Neustadt, DE
Tariq Ghayur · Holliston, US
Eve H. Barlow · Princeton, US
Martin Schmidt · Frankfurt am Main, DE
Axel Meyer · Frankfurt am Main, DE
Nicole Teusch · Uerdingen, DE

Key dates

Filing date	Aug 29, 2013
Grant date	Feb 9, 2016
Priority date	—
Expiry date	Aug 29, 2033

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.